Study of Alwextin® Cream in Treating Epidermolysis Bullosa
| Status: | Completed |
|---|---|
| Conditions: | Skin and Soft Tissue Infections |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 1/21/2018 |
| Start Date: | February 2009 |
| End Date: | November 2010 |
Open-label, Pilot Study to Investigate the Safety and Tolerability of Alwextin 3.0% Cream in the Treatment of Epidermolysis Bullosa
The purpose of this study is to determine how safe and effective allantoin 3% cream
(Alwextin) is in improving the healing of recurrent skin lesions and reducing overall
blistering in people with epidermolysis bullosa (EB). Allantoin 3% cream is applied topically
to the entire body once daily.
(Alwextin) is in improving the healing of recurrent skin lesions and reducing overall
blistering in people with epidermolysis bullosa (EB). Allantoin 3% cream is applied topically
to the entire body once daily.
Potential subjects came to the for a screening visit. Eligible subjects had baseline
assessments performed and were provided study medication, allantoin 3% cream. Subjects were
instructed to apply the study medication to the entire body once daily and to keep daily
record of study medication use. Subjects returned every 4 weeks for a total of 12 weeks for
repeat assessments.
assessments performed and were provided study medication, allantoin 3% cream. Subjects were
instructed to apply the study medication to the entire body once daily and to keep daily
record of study medication use. Subjects returned every 4 weeks for a total of 12 weeks for
repeat assessments.
Inclusion Criteria:
- history of epidermolysis bullosa
Exclusion Criteria:
- use of any skin product containing allantoin for 30 days prior to enrollment
We found this trial at
1
site
Click here to add this to my saved trials
